Premium
Short‐Term Administration of Selected Anti‐T‐Cell Receptor Vβ Chain Specific MoAb Reduces Sialadenitis in MRL/ lpr Mice
Author(s) -
SKARSTEIN K.,
HOLMDAHL R.,
JOHANNESSEN A. C.,
GOLDSCHMIDT T.,
JONSSON R.
Publication year - 1995
Publication title -
scandinavian journal of immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.934
H-Index - 88
eISSN - 1365-3083
pISSN - 0300-9475
DOI - 10.1111/j.1365-3083.1995.tb03691.x
Subject(s) - sialadenitis , t cell receptor , monoclonal antibody , cd8 , immunology , in vivo , antibody , t cell , medicine , receptor , pathology , microbiology and biotechnology , biology , antigen , immune system , salivary gland
Sialadenitis develops spontaneously in MRL/Mp mice bearing a lymphoproliferative gene, lpr (MRL/ Mp‐ lpr/lpr ). Based on recent observations of an oligoclonal expansion of T‐cell receptor (TCR) expressing Vβ chain families (Vβ4, Vβ8.1, 2, Vβ10b) in salivary glands of these mice we have initiated selective antibody therapy. Treatment with monoclonal antibodies (MoAb) specific for T cells expressing a mixture of TCR Vβ4, Vβ8.1, 2 and Vβ10b was applied to MRL/ lpr mice before and after the spontaneous development of Sialadenitis. The in vivo treatment with Vβ4, Vβ8.1, 2 and Vβ10b MoAb did not prevent the development of Sialadenitis. However, in animals with established Sialadenitis, treatment with the MoAb significantly decreased the inflammation compared with the control groups, Immuno‐histochemical staining of cell phenotypes demonstrated a change in the ratio of CD4/CD8 in the animals with established Sialadenitis. Altogether, these findings illustrate that it is possible to modulate Sialadenitis and infiltrate cell phenotypes in vivo in MRL/ lpr mice with specific anti‐TCR Vβ MoAb treatment.